0 CHECKOUT

Global Precision Medicine Market - Estimates and Forecasts Through (2015–2022)

  • ID: 3499330
  • November 2015
  • 280 pages
  • BIS Research
1 of 5
Global Precision Medicine Market to hit $88 billion by 2022

FEATURED COMPANIES

  • AB-Biotics Sa
  • Asuragen, Inc.
  • Caris Life Sciences
  • Glaxosmithkline Plc (Gsk)
  • Intel Corporation
  • Medtronic
  • MORE

Global Precision Medicine Market: Focus on Ecosystem, Sub-Markets, Therapeutics, Application, & Regions - Estimates and Forecasts Through (2015–2022)

The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January, 2015, a large number of research and development has been taken for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic areas affected by genetic mutations.

Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The main aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to Oncology, skin, respiratory, CNS, CVD, and infectious diseases among others. The patients are benefited indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB-Biotics Sa
  • Asuragen, Inc.
  • Caris Life Sciences
  • Glaxosmithkline Plc (Gsk)
  • Intel Corporation
  • Medtronic
  • MORE

1 Report Scope
1.1 Scope Of The Study
1.2 Precision Medicine: Report Coverage
1.3 Methodology
1.3.1 Research Methodology For The Global Market Study
1.3.1.1 Geographical Analysis
1.3.1.2 Demand Side & Supply Side Analysis
1.3.1.3 Data Synthesis And Bridging
1.3.2 Global Precision Medicine: Research Methodology
1.3.2.1 Key Data Point Sources
1.3.2.1.1 Data Points Taken From Secondary Sources
1.3.2.1.2 Data Points Taken From Primary Sources
1.4 Report Description

2 Executive Summary

3 Market Overview
3.1 Introduction
3.2 Market Timeline
3.3 Key Participants, Strategies & Developments
3.3.1 Government Agencies
3.3.2 Academic Institutions
3.3.3 Device & Service Providers
3.4 Key Market Strategies And Developments
3.4.1 Introduction
3.4.2 Partnerships, Agreements, And Collaborations
3.4.3 Mergers & Acquisitions
3.4.4 Product Development And Launch
3.4.5 Business Expansion/Contracts
3.4.6 Patents, Approvals And Certifications
3.4.7 Others (Events & Recognitions)

4 Market Dynamics
4.1 Introduction
4.2 Market Drivers
4.2.1 Patients Involvement In Personal Healthcare
4.2.2 Technologies Driving The Market (E.G. Next-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
4.2.3 Increase In Genetic Diseases
4.2.4 Potential For More Targeted Therapies
4.2.5 Integration Of Big Data Healthcare Companies With Pharma & Biotech Companies
4.3 Market Challenges
4.3.1 Potential Threat To Personal Data
4.3.2 High Diagnostic Cost As A Barrier
4.3.3 Potential Risk Of Hardware Or Software Failure
4.3.4 Stringent Regulations And Standards
4.3.5 Lack Of Awareness About The Possible Applications Of Precision Medicine
4.3.6 Reimbursement Policies And Regulatory Framework
4.3.7 Limited Knowledge About The Application Of Test And Techniques
4.3.8 Lack Of Research And Evidences Creating Hindrances In Its Application
4.4 Market Opportunities
4.4.1 Introduction Of Precision Medicine Solutions In Developing Economies
4.4.2 Downsizing The Cost Of Genome Sequencing To Three Digits

5 Industry Dynamics
5.1 Value Chain Analysis
5.1.1 Device Manufacturer & Drug Producers
5.1.2 Healthcare Providers
5.1.3 Healthcare Its Or Big Data Companies
5.1.4 Regulators
5.1.5 Third Party Payers
5.1.6 Patients
5.2 Porter Five Force Analysis
5.2.1 Bargaining Power Of Buyer (Patient)
5.2.2 Bargaining Power Of Supplier
5.2.3 Threat From Substitute
5.2.4 Threat From A New Entrant
5.2.5 Intensity Of Competitive Rivalry
5.3 Consortiums, Certification, Regulations, And Standards
5.3.1 Introduction
5.3.2 Regulatory Bodies
5.3.2.1 Food And Drug Administration (Fda)
5.3.2.2 Medicines And Healthcare Products Regulatory Agency (Mhra)
5.3.2.3 Therapeutic Goods Administration (Tga)-Australia
5.3.2.4 Conformité Européenne (Ce)
5.3.3 Consortiums
5.3.4 Alliances/Associations

6 Global Precision Medicine Market By Ecosystem Players
6.1 Introduction
6.1.1 Market Statistics
6.2 Pharmaceuticals And Biotechnology Companies
6.2.1 Key Market Trends, Developments And Participants
6.2.1.1 Market Trends
6.2.1.2 Market Developments
6.2.1.3 Key Participants
6.3 Diagnostic Companies
6.3.1 Key Market Trends, Developments And Participants
6.3.1.1 Market Trends
6.3.1.2 Market Developments
6.3.1.3 Key Participants
6.4 Healthcare It Specialists/ Big Data Companies
6.4.1 Key Market Trends, Developments And Participants
6.4.1.1 Market Trends
6.4.1.2 Market Developments
6.4.1.3 Key Participants
6.5 Clinical Laboratories
6.5.1 Key Market Trends, Developments And Participants
6.5.1.1 Regulatory Bodies And Compliances
6.5.1.2 Market Trends
6.5.1.3 Key Participants

7 Global Precision Medicine Market By Sub-Markets
7.1 Introduction
7.1.1 Market Statistics
7.2 Companion Diagnostics
7.3 Biomarker-Based Test
7.3.1 Role Of Biobanking Into Biomarker
7.3.2 Key Participants
7.4 Targeted Therapeutics
7.4.1 Key Participants
7.5 Pharmacogenomics (Pgx)
7.5.1 Key Market Trends, Developments And Participants
7.5.1.1 Market Trends
7.5.1.2 Market Developments
7.5.1.3 Key Participants
7.6 Molecular Diagnostics
7.7 Others
7.7.1 Next-Generation Sequencing
7.7.2 Consumer Genomics
7.7.2.1 Key Participants
7.7.3 3d Printing
8 Global Precision Medicine Market By Therapeutics
8.1 Introduction
8.1.1 Market Statistics
8.2 Cancer/Oncology
8.2.1 Market Statistics
8.2.2 Types Of Cancer
8.2.3 Drugs & Tests
8.2.4 Key Market Trends, Developments & Participants
8.2.4.1 Market Trends
8.2.4.2 Market Developments
8.2.4.3 Key Participants
8.3 Cardiovascular Disease (Cvd)
8.3.1 Market Statistics
8.3.2 Drugs & Tests
8.3.3 Market Trends & Market Developments
8.3.3.1 Market Trend
8.3.3.1.1 Market Developments
8.3.3.1.2 Key Participants
8.4 Central Nervous System
8.4.1 Market Statistics
8.4.2 Neurological
8.4.2.1 Neurological Drugs & Tests
8.4.3 Psychiatric Disorders
8.4.3.1 Psychiatric Disorder Drugs & Tests
8.4.4 Market Tends & Market Developments
8.4.4.1 Market Trends
8.4.4.2 Key Developments
8.4.4.3 Key Participants
8.5 Infectious Diseases
8.5.1 Market Statistics
8.5.2 Infectious Diseases Drugs & Tests
8.5.3 Market Developments & Participants
8.5.3.1 Key Developments
8.5.3.2 Key Participants
8.6 Others
8.6.1 Market Statistics
8.6.2 Market Trends, Developments & Participants
8.6.2.1 Market Trends
8.6.2.2 Key Developments
8.6.2.3 Key Participants

9 Global Precision Medicine Market By Geography
9.1 Introduction
9.1.1 Market Statistics
9.2 The Americas
9.2.1 North America
9.2.1.1 The U.S.
9.2.1.2 Canada
9.2.1.3 Others
9.2.1.4 Key Market Trends, Developments And Participants
9.2.1.4.1 Regulations And Compliances
9.2.1.4.2 Market Trends
9.2.1.4.3 Market Developments
9.2.1.4.4 Key Participants
9.2.2 South America
9.2.2.1 Key Market Trends, Developments And Participants
9.2.2.1.1 Regulations And Compliances
9.2.2.1.2 Market Trends
9.2.2.1.3 Key Participants
9.3 Europe
9.3.1 Key Market Trends, Developments And Participants
9.3.1.1 Regulations And Compliances
9.3.1.2 Market Developments
9.3.1.3 Key Participants
9.4 Asia-Pacific (Apac)
9.4.1 Key Market Trends, Developments And Participants
9.4.1.1 Market Developments
9.4.1.2 Key Participants
9.5 Rest Of The World/Midde East & Africa (Mea)
9.5.1 Africa
9.5.2 Middle East
9.5.3 Key Market Developments And Participants
9.5.3.1 Market Developments
9.5.3.2 Key Participants

10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Overview
10.1.2 Financials
10.1.2.1 Overall Financials
10.1.2.2 Financials By Segment
10.1.2.3 Financials By Region
10.1.3 Key Developments
10.1.4 SWOT Analysis
10.2 Almac Group, Ltd.
10.2.1 Overview
10.2.2 Financials
10.2.3 Key Developments
10.2.4 SWOT Analysis
10.3 Asuragen, Inc.
10.3.1 Overview
10.3.2 Financials
10.3.3 Key Developments
10.3.4 SWOT Analysis
10.4 Biomérieux Sa
10.4.1 Overview
10.4.2 Financials
10.4.2.1 Overall Financials
10.4.2.2 Financials By Region
10.4.2.3 Financials By Segment
10.4.3 Key Developments
10.4.4 SWOT Analysis
10.5 Cepheid Inc.
10.5.1 Overview
10.5.2 Financials
10.5.2.1 Overall Financials
10.5.2.2 Net Revenue By Segment
10.5.2.3 Net Revenue By Region
10.5.3 Key Developments
10.5.4 SWOT Analysis
10.6 Cetics Healthcare Technologies Gmbh
10.6.1 Overview
10.6.2 Financials
10.6.3 Key Developments
10.6.4 SWOT Analysis
10.7 GE Healthcare
10.7.1 Overview
10.7.2 Financials
10.7.2.1 Overall Financials
10.7.2.2 Net Revenue By Segment
10.7.2.3 Financial Summary
10.7.3 Key Developments
10.8 Glaxosmithkline Plc (Gsk)
10.8.1 Overview
10.8.2 Financials
10.8.2.1 Overall Financials
10.8.2.2 Financials By Segment
10.8.2.3 Financials By Region
10.8.2.4 Financials By Therapeutics
10.9 Intomics A/S
10.9.1 Overview
10.9.2 Financials
10.9.3 Key Developments
10.9.4 SWOT Analysis
10.1 Johnson & Johnson
10.10.1 Overview
10.10.2 Financials
10.10.2.1 Overall Financials
10.10.2.2 Net Revenue By Segment
10.10.2.3 Net Revenue By Region
10.10.3 Key Developments
10.11 Laboratory Corporation Of America Holdings
10.11.1 Overview
10.11.2 Financials
10.11.2.1 Overall Financials
10.11.2.2 Financials By Segment
10.11.3 Key Developments
10.11.4 SWOT Analysis
10.12 Medtronic
10.12.1 Overview
10.12.2 Financials
10.12.2.1 Overall Financials
10.12.3 Key Developments
10.13 Novartis
10.13.1 Overview
10.13.2 Financials
10.13.2.1 Overall Financials
10.13.2.2 Financials By Region
10.13.2.3 Financials By Segment
10.14 Pfizer Inc.
10.14.1 Overview
10.14.2 Financials
10.14.2.1 Overall Financials
10.14.2.2 Net Revenue By Segment
10.14.2.3 Net Revenue By Region
10.14.3 Key Developments
10.14.4 SWOT Analysis
10.15 Qiagen
10.15.1 Overview
10.15.1.1 Biobase Gmbh (Subsidiary)
10.15.1.1.1 Overview
10.15.2 Financials
10.15.2.1 Overall Financials
10.15.3 Key Developments (Biobase)
10.16 Quest Diagnostics Inc
10.16.1 Overview
10.16.2 Financials
10.16.2.1 Overall Financials
10.16.2.2 Net Revenue By Segment
10.16.3 Key Developments
10.16.4 SWOT Analysis
10.17 Randox Laboratories Ltd.
10.17.1 Overview
10.17.2 Financials
10.17.3 Key Developments
10.17.4 SWOT Analysis
10.18 Roche Holding Ag-Br
10.18.1 Overview
10.18.2 Financials
10.18.2.1 Overall Financials
10.18.2.2 Net Revenue By Segment
10.18.3 Key Developments
10.18.4 SWOT Analysis
10.19 Sanofi Pharma
10.19.1 Overview
10.19.2 Financials
10.19.2.1 Overall Financials
10.19.2.2 Net Revenue By Segment
10.2 Takeda Pharmaceutical Company Limited
10.20.1 Overview
10.20.2 Financials
10.20.2.1 Overall Financials
10.20.3 Key Developments
10.20.4 SWOT Analysis
10.21 Teva Pharmaceutical Industries Ltd.
10.21.1 Overview
10.21.2 Financials
10.21.2.1 Overall Financials
10.21.2.2 Net Revenue By Segment
10.21.2.3 Net Revenue By Segment
10.21.3 Key Developments
10.21.4 SWOT Analysis
10.22 Ab-Biotics Sa
10.22.1 Overview
10.23 Caris Life Sciences
10.23.1 Overview
10.24 Healthcore, Inc.
10.24.1 Overview
10.25 IBM
10.25.1 Overview
10.26 Innventis
10.26.1 Overview
10.27 Intel Corporation
10.27.1 Overview
10.28 Molecular Health Gmbh
10.28.1 Overview
10.29 Precision For Medicine
10.29.1 Overview

List of Tables
Table 1 Leading Companies In The Precision Medicine Market
Table 2 Factors Impacting The Buyer’s Bargaining Power
Table 3 Factors Impacting The Supplier’s Bargaining Power
Table 4 Factors Impacting The Threat From Substitute
Table 5 Factors Impacting The Threat From New Entrant
Table 6 Factors Impacting The Degree Of Competition
Table 7 Regulatory Bodies In Precision Medicine Market
Table 8 Consortiums In Precision Medicine Market
Table 9 Alliances/Associations in Precision Medicine Market
Table 10 Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
Table 11 Pharma & Biotech: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion)
Table 12 Pharma & Biotech: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion)
Table 13 Pharma & Biotech: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
Table 14 Key Developments In Pharma & Biotech Companies(2015)
Table 15 Diagnostic Tools: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion)
Table 16 Diagnostic Tools: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion)
Table 17 Diagnostic Tools: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
Table 18 Key Developments In Diagnostic Companies(2015)
Table 19 Healthcare Its/Big Data: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion)
Table 20 Healthcare Its/Big Data: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion)
Table 21 Healthcare Its/Big Data: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
Table 22 Key Developments In Healthcare It/Big Data Companies(2015)
Table 23 Clinical Laboratories: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion)
Table 24 Clinical Laboratories: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion)
Table 25 Clinical Laboratories: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
Table 26 Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion)
Table 27 Companion Diagnostics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 28 Companion Diagnostics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million)
Table 29 Biomarker: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 30 Biomarker: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million)
Table 31 Targeted Therapeutics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 32 Targeted Therapeutics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million)
Table 33 Pharmacogenomics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 34 Pharmacogenomics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million)
Table 35 Molecular Diagnostics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 36 Molecular Diagnostics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million)
Table 37 Other Sub-Markets: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 38 Other Sub-Markets: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million)
Table 39 Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Billion)
Table 40 Cancer: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
Table 41 Cancer: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion)
Table 42 Cancer: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
Table 43 Precision Medicine Drugs And Relevant Genes : Oncology
Table 44 Precision Medicine Genetic Tests With Respect To Oncology
Table 45 Key Developments (2013-2015)
Table 46 Cvd: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
Table 47 Cvd: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion)
Table 48 Cvd: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Million)
Table 49 Precision Medicine Drugs And Relevant Genes: Cardiovascular
Table 50 Precision Medicine Genetic Tests With Respect To Cardiovascular
Table 51 Key Developments(2014-2015)
Table 52 CNS: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 53 CNS: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Million)
Table 54 CNS: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Million)
Table 55 Precision Medicine Drugs And Relevant Genes: Neurology
Table 56 Precision Medicine Drugs And Relevantgenes: Psychiatric Disorders
Table 57 Precision Medicine Genetic Tests With Respect To Psychiatric Disorders
Table 58 Psychiatric Disorders: Key Developments (2014-2015)
Table 59 Infectious Disease: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 60 Infectious Disease: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Million)
Table 61 Infectious Disease: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Million)
Table 62 Precision Medicine Drugs And Relevant
Table 63 Other Therapeutics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 64 Other Therapeutics: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Million)
Table 65 Other Therapeutics: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Million)
Table 66 Precision Medicine Drugs And Relevant Genes: Other Diseases
Table 67 Precision Medicine Genetic Tests With Respect To Other Diseases
Table 68 Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
Table 69 Americas: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
Table 70 Americas: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
Table 71 Americas: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Billion)
Table 72 Europe: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
Table 73 Europe: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Billion)
Table 74 Apac: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
Table 75 Apac: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Million)
Table 76 Row: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million)
Table 77 Row: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Million)

List of Figures
Figure 1 Precision Medicine Market Study
Figure 2 Methodology
Figure 3 Different Phases Of Research Methodology For The Global Market
Figure 4 Precision Medicine Market: Research Methodology
Figure 5 Global Precision Medicine Market Share, By Ecosystem, 2014-2022 ($Billion)
Figure 6 Global Precision Medicine Market Size, By Sub-Market Type, 2014 – 2022 (Billion)
Figure 7 Global Precision Medicine Market Size, By Therpeutic Application, 2014 – 2022 (Billion)
Figure 8 Global Precision Medicine Market Size, By Geography, 2014 – 2022 ($Billion)
Figure 9 Timeline Of Precision Medicine
Figure 10 Precision Medicine: Benefits
Figure 11 Examples: Applied Areas Of Precision Medicine
Figure 12 Elements Of Precision Medicine Technology
Figure 13 Different Type Of Data Used By Big Data Companies
Figure 14 Precision Medicine: Areas Of Interest
Figure 15 Precision Medicine: Partnerships, Agreements, And Collaborations (2015)
Figure 16 Precision Medicine: Mergers & Acquisitions( 2015)
Figure 17 Precision Medicine: Key Product Launch & Developments (2015)
Figure 18 Precision Medicine: Key Business Expansions & Contracts ( 2015)
Figure 19 Precision Medicine: Key Patents/ Approvals ( 2015)
Figure 20 Precision Medicine: Events & Recognition (2015)
Figure 21 Market Drivers And Challenges
Figure 22 Benefits Of Precision Medicine To Patients
Figure 23 Precision Medicine Market Challenges: Impact Analysis
Figure 24 Major Barriers Caused By Regulation And Standards
Figure 25 Downsizing Cost Of Genome Sequencing
Figure 26 Flow Chart Of Precision Medicine
Figure 27 Value Chain Analysis
Figure 28 Precision Medicine Market: Porter Five Force Analysis
Figure 29 Roles And Responsibilities Of Healthcare Policy Makers
Figure 30 Role Of Fda In Precision Medicine
Figure 31 Classification Of Medical Devices
Figure 32 Global Precision Medicine Market By Ecosystem Players
Figure 33 Role Of Pharmaceuticals And Biotech Companies
Figure 34 Challenges Faced By Pharma & Biotech Companies
Figure 35 Diagnostic Tests Benefits For Stakeholders
Figure 36 Challenges Faced By Diagnostic Companies
Figure 37 Benefits Of Big Data
Figure 38 Transformation Of Medicine
Figure 39 Basic Ingredients Provided By Big Data For Precision Medicine
Figure 40 Challenges Faced By Big Data Companies
Figure 41 Oecd Recommendations On The Governance Of Clinical Trials
Figure 42 Types Of Precision Medicine Sub-Market
Figure 43 Benefits Of Companion Diagnostics
Figure 44 List Of Approved Companion Diagnostic Devices
Figure 45 Function Of Biomarkers
Figure 46 List Of Biobanks
Figure 47 Examples Of Biobanking Initiatives Across Selected Oecd Countries
Figure 48 Biobanks Services
Figure 49 Development In Pgx
Figure 50 Challenges Of Pgx Studies
Figure 51 Molecular Diagnostics: Application
Figure 52 Molecular Diagnostics: Benefits
Figure 53 Global Precision Medicine Market: By Therapeutics
Figure 54 Target Scope Of Precision Medicine By Cancer Types
Figure 55 Global Precision Medicine Market Classification, By Geography
Figure 56 Key Drivers For Precision Medicine: North America
Figure 57 Objectives Of The Precision Medicine Initiative
Figure 58 Apac: Market Challenges
Figure 59 Abbott: Overall Financials ($Billion), 2012-2014
Figure 60 Abbott: Net Revenue By Segments ($Billion), 2012-2014
Figure 61 Abbott: Net Revenue By Region, 2012-2014 ($Billion)
Figure 62 Abbott: SWOT Analysis
Figure 63 Almac: SWOT Analysis
Figure 64 Asuragen: SWOT Analysis
Figure 65 Biomerieux: Overall Financials ($Million), 2012-2014
Figure 66 Biomerieux: Net Revenue By Region, 2014
Figure 67 Biomerieux: Net Revenue By Segment, 2014
Figure 68 Biomerieux: SWOT Analysis
Figure 69 Cepheid: Overall Financials, 2012-2014 ($Million)
Figure 70 Cepheid: Net Revenue, By Segments, 2012-2014 ($Million)
Figure 71 Cepheid: Net Revenue, By Region, 2012-2014 ($Million)
Figure 72 Cepheid: SWOT Analysis
Figure 73 GE Corporation: Overall Financials, 2012-2014 ($Billion)
Figure 74 GE Corporation: Net Revenue, By Segments, 2012-2014 ($Million)
Figure 75 GSK: Overall Financials, 2012-2014 ($Billion)
Figure 76 GSK: Net Revenue By Segment, 2014 ($Billion)
Figure 77 GSK: Net Revenue By Region, 2014 ($Billion)
Figure 78 Gsk: Net Revenue By Therapeutics, 2014 ($Billion)
Figure 79 J&J: Overall Financials, 2012 - 2014 ($Billion)
Figure 80 J&J: Net Revenue By Segment, 2012 - 2014 ($Million)
Figure 81 J&J: Net Revenue By Region, 2012 - 2014 ($Million)
Figure 82 Labcorp: Overall Financials ($Million), 2012-2014
Figure 83 Net Revenue By Segments, 2012-2014($Million)
Figure 84 Labcorp: SWOT Analysis
Figure 85 Medtronic: Overall Financials, 2012 - 2014 ($Million)
Figure 86 Novartis: Overall Financials, 2012 - 2014 ($Billion)
Figure 87 Novartis: Net Revenue By Region, 2014 ($Billion)
Figure 88 Novartis: Net Revenue By Segment, 2014 ($Billion)
Figure 89 Pfizer: Overall Financials, 2012 – 2014 ($Billion)
Figure 90 Pfizer: Net Revenue, By Segment, 2012-2014 ($Million)
Figure 91 Pfizer: Net Revenue, By Region, 2012-2014 ($Billion)
Figure 92 Pfizer : SWOT Analysis
Figure 93 Qiagen: Overall Financials ($Million), 2012-2014
Figure 94 Qiagen: Net Revenue By Region ($Million), 2014
Figure 95 Qiagen: Net Revenue By Segment, 2014
Figure 96 Quest: Overall Financials, 2012 - 2014 ($Million)
Figure 97 Quest: Net Revenue, By Segment, 2012 - 2014 ($Million)
Figure 98 Quest: SWOT Analysis
Figure 99 Roche: Overall Financials, 2012-2014 ($Billion)
Figure 100 Roche: Net Revenue, By Segments, 2012-2014 ($Billion)
Figure 101 Roche: SWOT Analysis
Figure 102 Sanofi Pharma: Overall Financials, 2012-2014($Billion)
Figure 103 Sanofi Pharma: Net Revenue, By Segments, 2012-2014 ($Bilion)
Figure 104 Takeda: Overall Financials, 2012-2014 ($Billion)
Figure 105 Takeda: SWOT Analysis
Figure 106 Teva: Overall Financials, 2012 – 2014 ($Billion)
Figure 107 Teva: Net Revenue Share, By Segment (2014)
Figure 108 Teva: Net Revenue Share, By Region (2014)
Figure 109 Teva: SWOT Analysis

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • AB-Biotics Sa
  • Asuragen, Inc.
  • Caris Life Sciences
  • Glaxosmithkline Plc (Gsk)
  • Intel Corporation
  • Medtronic
  • MORE

Recently, in a speech at the White House, American President Obama unveiled his Precision Medicine Initiative, a two-hundred-and-fifteen-million-dollar plan to collect genetic information from a million American volunteers in order to further the development of personalized, genetics-based medical treatments. Obama called precision medicine “one of the greatest opportunities for new medical breakthroughs that we have ever seen.” Following this, the major French drug company Sanofi has recently announced that their Praluent drug can significantly reduce low-density lipoprotein cholesterol (LDL-C), which is often called “bad cholesterol.” The company further revealed that Praluent has received a green signal from the European Commission for treating adult patients suffering from hypercholesterolemia and LDL cholesterol.

Most of the advancements in this market are being driven by advancements in precision oncology techniques. As a result a patient diagnosed with cancer in 2004 would have had only a 10% chance of obtaining the right treatment for the disease as compared to a 70-80% chance of getting the right treatment today. With these crucial segments setting pace, the global precision market is set to be valued at close to $88 billion by 2022 at an estimated CAGR of 12.60% from 2015 to 2022 with North America and Europe setting pace for the Rest of the World, according to Global Precision Medicine Market – Estimation & Forecast (2015-2022) report.

The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), Government support and regulations. The main aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to Oncology, skin, respiratory, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease.

The report presents a thorough analysis of the entire precision medicine ecosystem and provides extensive insights of the different developments, trends and key participants. It also focuses on different sub-markets which help in the development of precision medicine solutions. While highlighting the principal driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliance, and regulatory bodies and their involvement in the precision medicine market. The report includes the profiles of major players in the precision medicine market that allows its readers to get an insight into the industry trends.

Note: Product cover images may vary from those shown
4 of 5

- AB-Biotics Sa

- Abbott Laboratories

- Almac Group, Ltd.

- Asuragen, Inc.

- Biobase Gmbh (Subsidiary)

- Biomérieux Sa

- Caris Life Sciences

- Cepheid Inc.

- Cetics Healthcare Technologies Gmbh

- GE Healthcare

- Glaxosmithkline Plc (Gsk)

- Healthcore, Inc.

- IBM
- Intel Corporation

- Intomics A/S

- Johnson & Johnson

- Laboratory Corporation Of America Holdings

- Medtronic

- Novartis

- Qiagen

- Quest Diagnostics Inc

- Randox Laboratories Ltd.

- Roche Holding Ag-Br

- Takeda Pharmaceutical Company Limited

- Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: A printed copy of the report will be shipped to you.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S